Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2007-12-04
2007-12-04
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S009200, C424S001110, C424S001650, C424S600000, C424S601000, C514S007600
Reexamination Certificate
active
10844747
ABSTRACT:
The present invention is directed towards novel cyclic phosph(oramid)ate prodrugs of alcohol-, amine-, and thiol-containing drugs, their preparation, their synthetic intermediates, and their uses. Another aspect of the invention is the use of the prodrugs to treat diseases that benefit from enhanced drug distribution to the liver and like tissues and cells that express cytochrome P450, including hepatitis, cancer, liver fibrosis, malaria, other viral and parasitic infections, and metabolic diseases where the liver is responsible for the overproduction of the biochemical end product, e.g. glucose (diabetes); cholesterol, fatty acids and triglycerides (hyperlipidemia) (atherosclerosis) (obesity). In one aspect, the invention is directed towards the use of the prodrugs to enhance oral drug delivery. In another aspect, the prodrugs are used to prolong pharmacodynamic half-life of the drug. In addition, the prodrug methodology of the current invention is used to achieve sustained delivery of the parent drug. In another aspect, the prodrugs are used to increase the therapeutic index of the drug. In another aspect of the invention, a method of making these prodrugs is described. In another aspect, the prodrugs are also useful in the delivery of diagnostic imaging agents to the liver.
REFERENCES:
patent: 3018302 (1962-01-01), Arnold et al.
patent: 3796700 (1974-03-01), Yoshioka et al.
patent: 4255566 (1981-03-01), Carrico et al.
patent: 4318982 (1982-03-01), Hornby et al.
patent: 4340668 (1982-07-01), Hornby et al.
patent: 4376165 (1983-03-01), Hornby et al.
patent: 4447529 (1984-05-01), Greenquist et al.
patent: 4952740 (1990-08-01), Juge et al.
patent: 5130303 (1992-07-01), Akiyama et al.
patent: 5663159 (1997-09-01), Starret, Jr. et al.
patent: 5962522 (1999-10-01), Wacher et al.
patent: 6004927 (1999-12-01), Benet et al.
patent: 6028054 (2000-02-01), Benet et al.
patent: 6312662 (2001-11-01), Erion et al.
patent: 6752981 (2004-06-01), Erion et al.
patent: 6946115 (2005-09-01), Erion et al.
patent: 2005/0288240 (2005-12-01), Erion et al.
patent: 0 481 214 (1992-04-01), None
patent: WO 90/08155 (1990-07-01), None
patent: WO 90/10636 (1990-09-01), None
patent: WO 98/39343 (1994-01-01), None
patent: WO 98/39342 (1997-03-01), None
patent: WO 98/09668 (1998-03-01), None
patent: WO 98/39344 (1998-09-01), None
patent: WO 99/45016 (1999-09-01), None
patent: WO 00/52015 (2000-09-01), None
Bedford et al., “Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4,”Bioorganic&Medicinal Chemistry Letters, 6(2):157-160 (1996).
Bentrude et al., “Stereo- and regiochemistries of the oxidations of 2-methoxy-5-tert-butyl-1,3,2-dioxaphosphorinanes and the cyclic methyl 3′, 5′—phosphate of thymidine by H2O/I2 and O2/AIBN to P-chiral phosphates. 170 NMR assignment of phosphorus configuration to the diastereomeric thymidine cyclic methyl 3′, 5- monophosphates,”J. Am. Chem. Soc., 111:3981-3987 (1989).
Farquhar et al., “Synthesis and biological evaluation of neutral derivatives of 5-fluoro-2′-deoxyuridine 5′—phosphate,”J. Org. Chem., 26:1153 (1983).
Farquhar et al., “Biologically-cleavable phosphate protective groups: 4-acyloxy-1,3,2-dioxaphosphorinanes as neutral latent precursors of dianionic phosphates,”Tetrahedron Lett., 36:655 (1995).
Hayakawa et al., “Benzimidazolium triflate as an efficient promoter for nucleotide synthesis via the phosphoramidite method,”J. Org. Chem., 61:7996 (1996).
Meier et al., “ADA-bypass by lipophiliccyclo-sal-ddAMP pro-nucleotides. A second example of the efficiency of thecycloSat-concept,”Bioorg. Med. Chem. Lett., 7:1577 (1997).
Nagamatsu et al., “New phosphorylating agents for general synthesis of mixed phosphate esters,”Tetrahedron Lett., 28:2375 (1987).
Nakayama et al., “A highly enantioselective synthesis of phosphate triesters,”J. Am. Chem. Soc., 112:6936 (1990).
Ogg et al., “A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro,”Xenobiotica, 29(3):269-279 (1999).
Shih et al., “Studies on potential antitumor agents (III). Synthesis of 4-arylcyclophosphamides,”Heterocycles, 9(9):1277-1285 (1978).
Wantanabe et al., “Dibenzyl phosphorofluoridate, a new phosphorylating agent,”Chem. Pharm. Bull., 38:562 (1990).
Yip et al.,-“Use of high-performance liquid chromatography in the preparation of flavin adenine dinucleotide analyte conjugates,”J. Chrom., 326:301-310 (1985).
Arnér, E.S.J. and Eriksson, S., “Mammalian Deoxyribonculeoside Kinases”Pharmac. Ther. 67(2): 155-186, Elsevier Science Ltd. (1995).
Bentrude, Wesley G., et al., “Conformations of Saturated Six-Membered-Ring Phosphorus Heterocycles Related to Cyclophosphamide. NMR, X-ray, and Infrared Studies of 2-Methoxy-2-oxo-1,3,2-oxazaphosphorinane and 2-Thio-1,3,2-oxazaphosphorinane,”J. Am.Chem Soc. 108:6669-6675, American Chemical Society (1986).
Bentrude, Wesley G., et al., “Conformations of Saturated Six-Membered-Ring Phosphorus Heterocycles. 2-Aryl-1,3,2λ5-oxazaphosphorinanes,”J. Am.Chem Soc. 110:7119-7127, American Chemical Society (1988).
Denmark, Scott E., et al., “Asymmetric Electrophilic Amination of Chiral Phosphorus-Stabilized Anions,”Tetrahedron48/11:2191-2208 Pergamon Press (1992).
De Waziers, I., et al., “Cytochrome P450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues,”J. Pharmacol. Exp. Ther. 253:387-394, American Society for Pharmacology and Experimental Therapeutics (1990).
Elliott, R.L., et al., “Synthesis and Biological Evaluation of Phosphonamidate Peptide Inhibitors of Enkephalinase and Angiotensin-Converting Enzyme,”J. Med. Chem. 28:1208-1216, American Chemical Society (1985).
Erion, M., et al., “Design, Synthesis, and Characterization of a Series of Cytochrome P4503A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver,”J. Am. Chem. Soc. 126:5154-5163, American Chemical Society (Apr. 2004).
Erion, M., et al., “Liver-Targeted Drug Delivery Using HepDirect Prodrugs,”J. Pharmacol. Exper. Ther. 312:554-560, American Society for Pharmacology and Experimental Therapeutics (Feb. 2005).
Erion, M., et al., “HepDirect Prodrugs for Targeting Nucleotide-Based Antiviral Drugs to the Liver,”Current Opinion in Investigational Drugs7/2:109-117, The Thomson Corporation (2006).
Freeman, Sally, et al., “Prodrug Design for Phosphates and Phosphonates,” Chapter 3 inProgress in Medicinal Chemistry, vol. 34, pp. 111-147, Elsevier Sciences BV (1997).
Gorenstein, D.G., et al., “Stereoelectronic Effects in the Reactions of Epimeric 2-Aryloxy-2-oxy-1,3,2-dioxaphosphorinanes and Oxazaphosphorinanes,”J. Am. Chem. Soc. 102: 5077-5081, American Chemical Society (1980).
Hulst, R., et al., “A New31P NMR Method for the Enantiomeric Excess Determination of Alcohols, Amines and Amino Acid Esters,”Tetrahedron Letters34(8):1339-1342, Pergamon Press Ltd. (1993).
Hunston, R.N., et al., “Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2′-Deoxy-5-fluorouridine,”J. Med Chem. 27:440-444, American Chemical Society (1984).
Khamnei, S. and Torrence, P.F., “Neighboring Group Catalysis in the Design of Nucleotide Prodrugs,”J. Med. Chem. 39:4109-4115, American Chemical Society (1996).
Lorey, M. and Meier, C. “A New Cyclic Phosphoramidate D4T Prodrug ApproachCycloAmb-D4T-Phosphoramidates,”Nucleosides&Nucleotides18(4&5):947-948, Marcel Dekker, Inc. (1999).
McGuigan, C., et al., “Kinase Bypass: A New Strategy for Anti-HIV Drug Design,”Bioorganic&Medicinal Chemistry Letters3/6:1207-1210, Pergamon Press Ltd. (1993).
Meier, C. et al., “Cyclic Saligen
Erion Mark D.
Reddy K. Raja
Lewis Patrick
Metabasis Therapeutics, Inc.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Prodrugs for liver specific drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prodrugs for liver specific drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs for liver specific drug delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861393